FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Estrogen receptor‐alpha (ERα)‐positive breast cancer is often treated with antihormonal regimens. However, resistance to treatment is common, leading to metastatic disease. ERα activity requires the functional involvement of pioneer factors FOXA1 and GATA3, which enable ERα–chromatin binding and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrijver, Willemijne, Schuurman, Karianne, van Rossum, Annelot, Droog, Marjolein, Jeronimo, Carmen, Salta, Sofia, Henrique, Rui, Wesseling, Jelle, Moelans, Cathy, Linn, Sabine C., van den Heuvel, Michel, van Diest, Paul, Zwart, Wilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210032/
https://www.ncbi.nlm.nih.gov/pubmed/29972720
http://dx.doi.org/10.1002/1878-0261.12353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210032/
https://www.ncbi.nlm.nih.gov/pubmed/29972720
http://dx.doi.org/10.1002/1878-0261.12353

Ejemplares similares